-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LrhdwReE+jRk/MA0PBZJQkmYT7LQ1MqnTRE3otLmVxXBkJbmXQEXcBDhrh+y6QIh idVKoO4DhYJOldrjmooyUw== 0000941302-99-000100.txt : 19990615 0000941302-99-000100.hdr.sgml : 19990615 ACCESSION NUMBER: 0000941302-99-000100 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19990614 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNSORB BIOTECH INC CENTRAL INDEX KEY: 0001025863 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-52837 FILM NUMBER: 99645884 BUSINESS ADDRESS: STREET 1: STE 201 STREET 2: 1204 KENSINGTON RD NW CITY: CALGARY ALBERTA CANA STATE: A0 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MILLS ERIN INVESTMENT CORP CENTRAL INDEX KEY: 0001008411 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 7501 KEELE ST STE 500 STREET 2: CONCORD ONTARIO CANADA CITY: L4K 1Y2 MAIL ADDRESS: STREET 1: 7501 KEELE ST STREET 2: STE 500 CITY: CONCORD ONTARIO CANA SC 13G/A 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13(d)-2(b) (Amendment No.1) SYNSORB BIOTECH INC. ------------------------------------------------------------------------ (Name of Issuer) Common Stock, par value $.01 per share ------------------------------------------------------------------------ (Title of Class of Securities) 87160V104 ------------------------------------------------------------------------ (CUSIP Number) June 1, 1999 ------------------------------------------------------------------------ (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) / X / Rule 13d-1(c) / / Rule 13d-1(d) CUSIP No. 87160V104 13G/A 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS The Erin Mills Development Corporation 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada NUMBER OF 5 SOLE VOTING POWER SHARES BENEFICIALLY 6 SHARED VOTING POWER 125,000 OWNED BY EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 8 SHARED DISPOSITIVE POWER 125,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 125,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.429% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTIONS BEFORE FILLING OUT CUSIP No. 87160V104 13G/A 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS The Erin Mills Investment Corporation 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada NUMBER OF 5 SOLE VOTING POWER SHARES BENEFICIALLY 6 SHARED VOTING POWER 125,000 OWNED BY EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 8 SHARED DISPOSITIVE POWER 125,000 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 125,000 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.429% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTIONS BEFORE FILLING OUT STATEMENT ON SCHEDULE 13G This Amendment No.1 to Schedule 13G (the "Schedule 13G") relates to the common stock, par value $.01 per share ("Common Stock"), of SYNSORB Biotech Inc. (the "Company"), and is being filed as an amendment to the initial statement on Schedule 13G filed with the Securities and Exchange Commission ("the Commission") on February 17, 1998. This statement is being filed on behalf of The Erin Mills Development Corporation, an Ontario, Canada corporation ("EMDC"), as the indirect beneficial owner of the shares of Common Stock reported as beneficially owned in this statement, and The Erin Mills Investment Corporation, an Ontario, Canada corporation and majority owned subsidiary of EMDC ("TEMIC"), as the direct beneficial owner of the shares of Common Stock reported as beneficially owned in this statement. Schedule 13G is hereby amended and supplemented as follows: ITEM 1(A) NAME OF ISSUER. SYNSORB Biotech Inc. ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: Suite 201, 1204 Kensington Road N.W. Calgary, Alberta, T2N 3P5 CANADA ITEM 4 OWNERSHIP. See Items 5 through 11 on page 2 for EMDC and page 3 for TEMIC. ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following [ X ]. EXHIBITS EXHIBIT 1 Joint Filing Agreement dated June 9, 1999 between TEMIC and EMDC. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: June 14, 1999 THE ERIN MILLS DEVELOPMENT CORPORATION By: /s/ Gerry Quinn ---------------------------- Gerry Quinn Executive Vice-President THE ERIN MILLS INVESTMENT CORPORATION By: /s/ Gerry Quinn ---------------------------- Gerry Quinn President EXHIBIT INDEX EXHIBIT DESCRIPTION - ------- ----------- 1 Joint Filing Agreement dated June 9, 1999 between TEMIC and EMDC. EX-99 2 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $.01 per share, of SYNSORB Biotech Inc., and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings. The undersigned further agree that each party hereto is responsible for timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument. IN WITNESS WHEREOF, the undersigned have executed this Agreement as of June 9, 1999. THE ERIN MILLS DEVELOPMENT CORPORATION By: /s/ Gerry Quinn ---------------------------- Gerry Quinn Executive Vice-President THE ERIN MILLS INVESTMENT CORPORATION By: /s/ Gerry Quinn ---------------------------- Gerry Quinn President -----END PRIVACY-ENHANCED MESSAGE-----